
Topic
Biosimilars
Follow-on biologics, reference-product erosion, payer switching, launch sequencing, and specialty-channel uptake.

Global· July 24, 2026 · 17 min read
By Ran Chen#Biosimilars#EMA#FDA Approval

Deals· July 24, 2026 · 16 min read
Sun Pharma's $11.75B Organon Buy: India's Largest Drugmaker Bets on Women's Health
By Ran Chen#M&A#Biosimilars

Policy· July 15, 2026 · 22 min read
The Post-CREATES REMS Moat Map: Safety Programs Shielding Brands After the Fix
By Ran Chen#REMS#Biosimilars#Generic Entry

Pricing & Access· July 12, 2026 · 20 min read
Severe Asthma Biologics: Access and Phenotype Matching Guide
By Ran Chen#Payer Coverage#Payer Criteria#Respiratory

Pricing & Access· July 6, 2026 · 16 min read
Merck Portfolio Dossier: Keytruda QLEX, the Januvia Cliff, and a Post-2028 Pipeline
By Ran Chen#Purple Book#Orange Book#Biosimilars

Biosimilars· June 29, 2026 · 18 min read
Soliris Biosimilar Cliff: NMOSD Exclusivity Expiry and Payer Step Edits
By Ran Chen#Biosimilars#Interchangeability#Payer Policy

Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Biosimilars· June 24, 2026 · 17 min read
Darzalex Biosimilar Tracker: SC vs IV Formulations and the 2029 Market Entry Window
By Ran Chen#Biosimilars#Purple Book#Oncology

Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars

Pricing & Access· June 24, 2026 · 26 min read
Roche Genentech Portfolio Dossier: Subcutaneous Biologic Transitions
By Ran Chen#Purple Book#Biosimilars#J-Code